Carregant...
Pioglitazone and cardiovascular risk reduction: time for a second look?
Insulin resistance, a fundamental pathophysiological abnormality in patients with type 2 diabetes, is associated with increased cardiovascular (CV) disease risk. In diabetes management, the macrovascular impact of antihyperglycemic agents that do not improve insulin sensitivity has generally been di...
Guardat en:
| Publicat a: | Cardiovasc Endocrinol |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wolters Kluwer Health
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6768516/ https://ncbi.nlm.nih.gov/pubmed/31646121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/XCE.0000000000000110 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|